Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 8238 results

  1. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    In development Reference number: GID-TA11492 Expected publication date: TBC

  2. Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]

    Awaiting development Reference number: GID-TA11870 Expected publication date: TBC

  3. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    Awaiting development Reference number: GID-TA11869 Expected publication date: TBC

  4. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596

    In development Reference number: GID-TA11802 Expected publication date: TBC

  5. Leadless cardiac pacemaker implantation for bradyarrhythmias

    In development Reference number: GID-IPG10340 Expected publication date:  25 February 2026

  6. Invoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

  7. Artificial intelligence software to help detect and characterise colorectal polyps

    In development Reference number: GID-DG10118 Expected publication date: TBC

  8. NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

    Topic prioritisation

  9. Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential

    Topic prioritisation

  10. Transarterial radio embolisation for osteosarcoma liver metastases

    Topic prioritisation

  11. Cryoablation for Desmoid-type Fibromatosis

    Topic prioritisation

  12. Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

    Awaiting development Reference number: GID-TA11892 Expected publication date: TBC

  13. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576

    In development Reference number: GID-TA11773 Expected publication date: TBC

  14. Fertility problems: assessment and treatment - update 1 and 2

    In development Reference number: GID-NG10263 Expected publication date:  19 March 2026

  15. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC